
    
      Treatment:

      The Patients will receive Linagliptin 5 mg QD or placebo for a period of 6 months.

      The echocardiography and 24h RR measurement will be performed at baseline and 6 months after
      initiation of the therapy.

      The blood chemistry (Glucose, HbA1c, BNP) will be evaluated at baseline as well as 3 and 6
      months after initiation of the therapy.
    
  